1
|
Rooth C: Ovarian cancer: Risk factors,
treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Collins Y, Holcomb K, Chapman-Davis E,
Khabele D and Farley JH: Gynecologic cancer disparities: A report
from the Health Disparities Taskforce of the Society of Gynecologic
Oncology. Gynecol Oncol. 133:353–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Bocheva Y, Bochev P and Ivanov S: Ca-125
in diagnosis and monitoring of patients with ovarian cancer. Akush
Ginekol (Sofiia). 54:11–7. 2015.PubMed/NCBI
|
5
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Smith GP: Filamentous fusion phage: Novel
expression vectors that display cloned antigens on the virion
surface. Science. 228:1315–1317. 1985. View Article : Google Scholar : PubMed/NCBI
|
8
|
Parmley SF and Smith GP:
Antibody-selectable filamentous fd phage vectors: Affinity
purification of target genes. Gene. 73:305–318. 1988. View Article : Google Scholar : PubMed/NCBI
|
9
|
Velasco-Velázquez M, Xolalpa W and Pestell
RG: The potential to target CCL5/CCR5 in breast cancer. Expert Opin
Ther Targets. 18:1265–1275. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bastien JI, McNeill KA and Fine HA:
Molecular characterizations of glioblastoma, targeted therapy, and
clinical results to date. Cancer. 121:502–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Henry KA, Arbabi-Ghahroudi M and Scott JK:
Beyond phage display: Non-traditional applications of the
filamentous bacteriophage as a vaccine carrier, therapeutic
biologic, and bioconjugation scaffold. Front Microbiol. 6:7552015.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Kaplan G and Gershoni JM: A general insert
label for peptide display on chimeric filamentous bacteriophages.
Anal Biochem. 420:68–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Silacci M, Brack S, Schirru G, Mårlind J,
Ettorre A, Merlo A, Viti F and Neri D: Design, construction, and
characterization of a large synthetic human antibody phage display
library. Proteomics. 5:2340–2350. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lee KJ, Lee JH, Chung HK, Ju EJ, Song SY,
Jeong SY and Choi EK: Application of peptide displaying phage as a
novel diagnostic probe for human lung adenocarcinoma. Amino Acids.
48:1079–1086. 2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Che YJ, Wu HW, Hung LY, Liu CA, Chang HY,
Wang K and Lee GB: An integrated microfluidic system for screening
of phage-displayed peptides specific to colon cancer cells and
colon cancer stem cells. Biomicrofluidics. 9:0541212015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ma CI, Yin G, Yan D, He X, Zhang L, Wei Y
and Huang Z: A novel peptide specifically targeting ovarian cancer
identified by in vivo phage display. J Pept Sci. 19:730–736. 2013.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang L, Yin G, Yan D, Wei Y, Ma C, Huang
Z, Liao X, Yao Y, Chen X and Hao B: In vitro screening of ovarian
tumor specific peptides from a phage display peptide library.
Biotechnol Lett. 33:1729–1735. 2011. View Article : Google Scholar : PubMed/NCBI
|